• Diuron (3-(3,4-dichlorophenyl)-1,1-dimethylurea): Toxicology

  2026-08-06

  Diuron empowers researchers to probe photosynthetic inhibition and acute renal injury with high precision. This guide translates the latest mechanistic breakthroughs into optimized workflows and troubleshooting strategies for plant biology and environmental toxicology labs.

• Methylation Pathways in Neurological Disorders: SAMe's Clini

  2026-08-05

  This review by Bottiglieri et al. synthesizes evidence on S-adenosylmethionine (SAMe) as a pivotal methyl donor in CNS function and explores its therapeutic potential across diverse neurological disorders. The paper clarifies links between methylation deficits, vitamin status, and neuropsychiatric pathology, highlighting the translational value of targeting methyl pathways for neuroprotection and cognitive enhancement.

• Canagliflozin as an SGLT2 Inhibitor: Protocols for Renal Res

  2026-08-05

  Canagliflozin empowers diabetes and kidney disease researchers to model SGLT2 inhibition with precision, impacting mitochondrial remodeling and renal protection. This guide details actionable workflows, troubleshooting strategies, and the latest experimental insights, positioning APExBIO's Canagliflozin at the forefront of metabolic and renal research.

• Sulfaphenazole Restores Perfusion in Ischemic Skin Injury Mo

  2026-08-04

  The referenced study demonstrates that sulfaphenazole, a potent CYP2C9 inhibitor, significantly reduces the severity of pressure and thermal injuries in a murine model by rapidly restoring tissue perfusion. These findings highlight the compound’s therapeutic potential in mitigating ischemia–reperfusion injury and improving wound healing outcomes in settings of vascular dysfunction.

• γH2AX DNA Damage Detection Kit: Sensitive DSB Biomarker Assa

  2026-08-04

  The γH2AX DNA Damage Detection Kit (Mouse mAb/Red) enables precise, immunofluorescent detection of DNA double-strand breaks (DSBs) via γ-H2AX, a validated biomarker of genomic instability. APExBIO’s kit provides reproducible visualization of DSBs in mammalian cells and tissues, supporting quantitative DNA damage and repair research with high-content imaging. This article details biological rationale, mechanistic insights, validated benchmarks, and integration strategies for robust genotoxicity and apoptosis assessment.

• Ciclesonide in Translational Asthma Research: Protocols & In

  2026-08-03

  Ciclesonide’s prodrug activation and potent glucocorticoid receptor binding empower translational researchers to model airway inflammation and anti-inflammatory signaling with high fidelity. This article bridges experimental workflows and next-generation targeted degradation strategies, offering actionable parameters, troubleshooting, and unique insights into protocol optimization for respiratory disease research.

• SmD2 Acetylation and PARP Inhibitor Sensitivity in HCC

  2026-08-03

  This study uncovers how acetylation-dependent regulation of the spliceosomal protein SmD2 modulates DNA damage response and sensitivity to PARP inhibitors in hepatocellular carcinoma (HCC). It provides mechanistic insight into how targeting SmD2 acetylation, particularly via HDAC2 inhibition, can enhance PARP inhibitor efficacy, suggesting new therapeutic strategies for HCC beyond BRCA-mutant contexts.

• EZ Cap™ Cas9 mRNA (5-moUTP): Next-Gen Precision for Neurodeg

  2026-08-02

  Discover how EZ Cap™ Cas9 mRNA (5-moUTP) transforms CRISPR-Cas9 genome editing in neurodegeneration research. This article uniquely explores molecular stability, immunogenicity, and assay design, setting a new benchmark for precision gene editing in CNS and zebrafish models.

• Pepstatin A: Precision Aspartic Protease Inhibitor for Resea

  2026-08-01

  Pepstatin A is a highly selective aspartic protease inhibitor essential for dissecting viral protein processing and osteoclast differentiation in biomedical research. Its potency against enzymes such as pepsin, renin, HIV protease, and cathepsin D is well documented, with distinct IC50 values under defined conditions. APExBIO supplies ultra-pure Pepstatin A (SKU A2571), ensuring reproducibility and workflow integration.

• Procainamide Hydrochloride Protects Against Cisplatin Toxici

  2026-07-31

  The referenced study systematically evaluates the feasibility of using procainamide hydrochloride alongside cisplatin in pregnant mice. Results show that procainamide does not exacerbate cisplatin's embryotoxic effects and may offer partial protection against fetal toxicity, providing mechanistic insight for chemoprotective strategies in oncology research involving pregnancy.

• Necrostatin 2 (Nec-2): Unraveling Necroptosis in Immunometab

  2026-07-31

  Explore how Necrostatin 2 (Nec-2) advances research into necroptosis inhibition and immunometabolic regulation. This article delivers a unique, mechanistic perspective on RIPK2 targeting in inflammatory and liver disease models.

• Defining Proteoform-Specific Drug Interactions in Native Mem

  2026-07-30

  This study pioneers native top-down mass spectrometry to characterize proteoform-specific drug interactions in membrane proteins within their natural lipid environment. The findings reveal how post-translational modifications shape drug binding and off-target effects, offering new routes for precision pharmacology and safer therapeutic design.

• Apicidin as a Histone Deacetylase Inhibitor: Protocols & Ins

  2026-07-30

  Apicidin is a selective histone deacetylase inhibitor that empowers researchers to dissect cancer epigenetics and reproductive toxicology with nanomolar precision. This article delivers actionable protocols, troubleshooting guidance, and cross-domain applications, drawing on recent breakthroughs and APExBIO's rigorous product standards.

• Targeted SPP1 Inhibition in TAMs Reduces Tumor Burden

  2026-07-29

  This study introduces a phenotypic screening platform to identify small molecule modulators capable of reducing SPP1 expression in tumor-associated macrophages (TAMs), culminating in the development of a TAM-targeted nanoformulation. The findings reveal that direct SPP1 inhibition in TAMs leads to significant tumor regression in preclinical models, offering a novel therapeutic avenue for targeting the tumor microenvironment.

• C8-HSL Promotes Lung Cancer Progression via PI3K/AKT/ERK Act

  2026-07-29

  This study reveals that N-octanoyl-L-Homoserine lactone (C8-HSL), a bacterial quorum-sensing molecule, accelerates proliferation, migration, and invasion of lung cancer cells through PI3K/AKT/ERK pathway activation. The findings identify C8-HSL as a potential microbial risk factor in lung cancer and provide a mechanistic framework for targeting bacterial communication in infection biology research.

454 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page